STAT3 and T-cell large granular lymphocyte leukemia: Both T-LGLL and CLPD-NK showed a significantly shorter time-to-therapy in STAT3-mutated vs. nonmutated patients, which was more evident in non-Y640F STAT3-mutated cases (i.e., G618R, N647I, 656ins, D661V, and D661Y) compared to Y640F-mutated ones; these preliminary results confirm and extend recent reports on the potential impact of the type of STAT3 mutation on different clinical manifestations of T/NK-LGLL [33].